Dubai Telegraph - Vaccine supply outstrips demand, access inequity remains

EUR -
AED 3.938479
AFN 73.284283
ALL 98.19234
AMD 417.267449
ANG 1.943348
AOA 978.447316
ARS 1071.53141
AUD 1.629089
AWG 1.930079
AZN 1.82711
BAM 1.955647
BBD 2.17713
BDT 128.849948
BGN 1.955747
BHD 0.406468
BIF 3183.551653
BMD 1.072266
BND 1.425189
BOB 7.467417
BRL 6.152562
BSD 1.078316
BTN 90.972903
BWP 14.300884
BYN 3.528725
BYR 21016.42052
BZD 2.17343
CAD 1.49386
CDF 3073.115756
CHF 0.939162
CLF 0.03726
CLP 1028.119797
CNY 7.698019
CNH 7.63378
COP 4640.937963
CRC 551.556973
CUC 1.072266
CUP 28.415058
CVE 110.256399
CZK 25.259812
DJF 192.015021
DKK 7.459869
DOP 64.934934
DZD 142.958848
EGP 52.835878
ERN 16.083995
ETB 133.503285
FJD 2.399951
FKP 0.820465
GBP 0.830088
GEL 2.916983
GGP 0.820465
GHS 17.683621
GIP 0.820465
GMD 76.671173
GNF 9295.27488
GTQ 8.33535
GYD 225.592402
HKD 8.336174
HNL 27.205878
HRK 7.386875
HTG 141.888931
HUF 407.236454
IDR 16786.168917
ILS 4.020796
IMP 0.820465
INR 90.481213
IQD 1412.489812
IRR 45134.375558
ISK 148.766647
JEP 0.820465
JMD 171.076654
JOD 0.760348
JPY 163.686863
KES 139.08915
KGS 92.433433
KHR 4378.658423
KMF 493.644665
KPW 965.039476
KRW 1499.246878
KWD 0.328832
KYD 0.89853
KZT 530.808592
LAK 23665.153893
LBP 96559.167469
LKR 315.465391
LRD 204.33406
LSL 18.869628
LTL 3.166124
LVL 0.648604
LYD 5.232592
MAD 10.648369
MDL 19.338491
MGA 4988.610841
MKD 61.610194
MMK 3482.679288
MNT 3643.561097
MOP 8.633826
MRU 42.957649
MUR 49.75717
MVR 16.566921
MWK 1869.754141
MXN 21.634265
MYR 4.699212
MZN 68.521819
NAD 18.869628
NGN 1788.626462
NIO 39.676905
NOK 11.794827
NPR 145.556645
NZD 1.797446
OMR 0.412628
PAB 1.078316
PEN 4.044584
PGK 4.328662
PHP 62.679371
PKR 299.424042
PLN 4.325898
PYG 8431.342275
QAR 3.931893
RON 4.977143
RSD 117.04113
RUB 104.99181
RWF 1478.084695
SAR 4.02742
SBD 8.943509
SCR 14.390377
SDG 644.972153
SEK 11.594849
SGD 1.4214
SHP 0.820465
SLE 24.501684
SLL 22484.885861
SOS 616.251927
SRD 37.497551
STD 22193.748611
SVC 9.435264
SYP 2694.101668
SZL 18.864528
THB 36.687634
TJS 11.462006
TMT 3.763655
TND 3.347839
TOP 2.511359
TRY 36.822021
TTD 7.327428
TWD 34.580984
TZS 2878.975413
UAH 44.514627
UGX 3946.692121
USD 1.072266
UYU 45.046486
UZS 13787.924411
VEF 3884341.194834
VES 47.874003
VND 27101.532073
VUV 127.301648
WST 3.003615
XAF 655.905833
XAG 0.031788
XAU 0.000394
XCD 2.897854
XDR 0.808437
XOF 655.905833
XPF 119.331742
YER 267.878982
ZAR 19.79817
ZMK 9651.687743
ZMW 29.35571
ZWL 345.269328
  • RBGPF

    61.4000

    61.4

    +100%

  • RELX

    0.3200

    47.98

    +0.67%

  • VOD

    -0.0100

    9.31

    -0.11%

  • NGG

    -0.3600

    63.94

    -0.56%

  • GSK

    -0.3700

    36.29

    -1.02%

  • CMSC

    0.1600

    24.84

    +0.64%

  • RYCEF

    0.0100

    7.15

    +0.14%

  • RIO

    -3.0400

    64.43

    -4.72%

  • AZN

    -0.2000

    64.49

    -0.31%

  • BTI

    -0.0100

    35.39

    -0.03%

  • BP

    -0.8800

    28.93

    -3.04%

  • SCS

    0.0600

    13.14

    +0.46%

  • JRI

    0.1600

    13.53

    +1.18%

  • BCC

    1.4700

    142.32

    +1.03%

  • BCE

    0.3000

    28.37

    +1.06%

  • CMSD

    0.2350

    25.125

    +0.94%

Vaccine supply outstrips demand, access inequity remains
Vaccine supply outstrips demand, access inequity remains

Vaccine supply outstrips demand, access inequity remains

After two years of racing to vaccinate the world against Covid-19, the number of available doses now surpasses demand in many areas.

Text size:

Yet a yawning gap remains in vaccination rates between the richest and poorest countries.

On Friday, Gavi, which co-leads the Covax global distribution scheme, is holding a summit calling for more funds to address the issue of inequality in vaccine access.

- Huge production -

More than 13 billion doses have been produced since the pandemic, 11 billion of which have been administered, according to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

Science research group Airfinity expect nine billion more doses to be produced this year. Pfizer alone plans to make four billion doses.

Yet demand could fall to six billion doses this year, IFPMA's director general Thomas Cueni said.

"Since mid-2021, global vaccine production has exceeded global vaccine demand and this gap has continuously risen," Cueni told AFP.

By next year, production could exceed demand by 1.3 to 3.1 billion doses, he added.

Many richer nations are now approaching oversupply. European Union and G7 countries had a surplus of 497 million doses at the end of last month.

There are fears that doses could go to waste. Covid vaccines have a relatively short shelf-life -- AstraZeneca and Novavax's jabs have a six-month expiry date.

Airfinity says 241 million doses have passed their sell-by date so far during the pandemic.

- Billions unvaccinated -

Nevertheless, billions of people remain unvaccinated around the world, most of them in developing nations.

Covax, an international public-private partnership co-led by WHO and Gavi, has delivered 1.4 billion doses to 145 countries -- far short of the planned two billion doses by end-2021.

World Health Organization chief Tedros Adhanom Ghebreyesus has warned that inequality in vaccine access could lead to the emergence of new, possibly more contagious variants.

The WHO wants 70 percent of every country's population vaccinated by July.

But records are uneven.

Nearly 80 percent of France's population, for example, has received two doses. But only 15 percent of the population on the continent of Africa is fully vaccinated, according to Oxford University data.

An average of 42 percent of the population of 92 low- and middle-income countries participating in Covax have had one dose.

"Vaccine inequity is the biggest moral failure of our times and people and countries are paying the price," UN Secretary-General Antonio Guterres said earlier this year.

Covax says it now has enough doses to vaccinate around 45 percent of the population in the 92 countries receiving donations. But 25 of those countries lack the infrastructure for an effective immunisation campaign.

Making matters worse, many developing countries are being donated doses too close to their expiry date.

UNICEF's supply division director Etleva Kadilli said that in December almost more than 100 million doses had been refused, "the majority due to product shelf life".

Gavi has ruled that doses must be valid for at least 10 weeks on arriving in countries.

- Patent gridlock -

Countries like South Africa and India have long called for the World Trade Organization to suspend intellectual property rights for vaccines and anti-Covid treatments, so they can massively boost production.

After fierce opposition from pharmaceutical giants, a first compromise was reached between the United States, European Union, India and South Africa last month.

But several key countries like Switzerland have yet to sign on. Doctors Without Borders also says there are "key limitations" in the deal, such as covering only vaccines and geographical limits.

Pharmaceutical companies argue that patents are not the real problem.

Cueni of IFPMA, a big pharma lobby group, said the problem was now logistics.

"What we need is money to have storage, transportation, more trained health workers, campaigns to counter misinformation: these are the real challenges and not the patent waiver," he said.

- New variants -

Current vaccines target the virus that swept the world in 2020. While they greatly reduce the risk of serious illness from Covid, they only provide partial protection -- particularly against newer variants such as the now dominant Omicron.

Several vaccine manufacturers have begun testing jabs that target Omicron. They have hit delays but could be available in a few months, if approved by health authorities.

And despite the billions yet to receive a first dose, the United States, Britain, France and Israel have started rolling out a fourth, starting with the most vulnerable.

On Wednesday, the EU's medicines watchdog approved a second booster for people aged 80 years and over.

"No country can boost its way out of the pandemic," Tedros has warned.

lem-ic-burs-dl/jm

I.Menon--DT